New trial
A Phase 1b Study of BCL-XL Degrader DT2216 in Combination With Weekly Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
- Trial ID
- NCT06964009 on ClinicalTrials.gov
- Cancer type
- Ovarian, Fallopian, or Primary Peritoneal Cancer
- Published in
- New in Oncology - May 21, 2025
Dana Farber is investigating the maximum tolerable dose of DT2216—a selective BCL-xL degrader—administered with weekly paclitaxel in patients with recurrent platinum-resistant ovarian cancer, using a Bayesian Optimal Interval design to guide dose escalation and de-escalation.
More in ovarian cancer
-
Trial result · Oct 22, 2026 · NCT07213804
Sofetabart mipitecan (FRα-targeted ADC) posts 50.5% ORR and 8.1-mo mPFS in heavily pretreated HGOC—without keratopathy -
New trial · Oct 15, 2026 · NCT07851025
Phase 3 TREVI-OC-02 tests FRα-targeted torvutatug samrotecan plus bevacizumab maintenance in HRD-negative ovarian cancer -
New trial · Oct 15, 2026 · NCT07504588
Phase 2 NRG-GY038 compares sacituzumab govitecan plus bevacizumab with platinum-based treatment after PARP-inhibitor progression -
New trial · Oct 15, 2026 · NCT07776691
Phase 3 REJOICE-Ovarian04 tests CDH6-targeted raludotatug deruxtecan maintenance with or without bevacizumab -
New trial · Oct 8, 2026 · NCT07816666
Phase 3 torvutatug samrotecan FRα (FOLR1) ADC with exatecan (topoisomerase I) payload